Most Popular
-
1
Korea’s homegrown nanosatellite successfully launches into space
-
2
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
3
Nicaragua shuts down Seoul embassy
-
4
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
5
Hybe's multilabel system tested amid conflict with Ador
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
7
SNU profs to suspend treatment for one day
-
8
SK hynix pledges W20tr to ramp up DRAM production at home
-
9
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
10
Pianist Cho Seong-Jin named Berlin Philharmonic's artist-in-residence
CrystalGenomics appoint Gavin Choy as CEO of CG Pharmaceuticals
By Lim Jeong-yeoPublished : Oct. 8, 2020 - 15:04
CrystalGenomics on Thursday said it appointed Gavin Choy as the CEO of its US subsidiary, CG Pharmaceuticals.
Choy has 27 years of experience in researching and developing anticancer and antiviral treatments, as well as four successful clinical trial design applications with the US Food and Drug Administration, CrystalGenomics said.
At his new post, Choy will help CrystalGenomics advance its COVID-19 treatment pipeline for pancreatic cancer treatment research in the US.
Choy holds a doctorate in pharmacology from the University of Southern California. He has held roles as a clinical pharmacist at Stanford Health Care, clinical scientist at Gilead Sciences and vice president of Astex Pharmaceuticals, a US subsidiary of Otsuka Pharmaceutical.
Choy’s most recent position was at Apollomics, a cancer treatment development biotech, where he served as the chief operating officer since 2016.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
Choy has 27 years of experience in researching and developing anticancer and antiviral treatments, as well as four successful clinical trial design applications with the US Food and Drug Administration, CrystalGenomics said.
At his new post, Choy will help CrystalGenomics advance its COVID-19 treatment pipeline for pancreatic cancer treatment research in the US.
Choy holds a doctorate in pharmacology from the University of Southern California. He has held roles as a clinical pharmacist at Stanford Health Care, clinical scientist at Gilead Sciences and vice president of Astex Pharmaceuticals, a US subsidiary of Otsuka Pharmaceutical.
Choy’s most recent position was at Apollomics, a cancer treatment development biotech, where he served as the chief operating officer since 2016.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
